XML 66 R58.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
May 13, 2021
Dec. 02, 2020
Sep. 30, 2020
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Oct. 31, 2016
Loss Contingencies [Line Items]                
Research and development       $ 2,547,000 $ 1,938,000 $ 7,145,000 $ 8,099,000  
Revenue Share Agreement | Oncimmune Limited                
Loss Contingencies [Line Items]                
Royalty expense       500,000 200,000 $ 1,100,000 600,000  
Percentage of license agreement and royalty payment related to Nodify CDT test recognized revenue for non-screening tests           8.00%    
Minimum annual volume percentage thereafter           5.00%    
Bio-Rad License                
Loss Contingencies [Line Items]                
License expiry date           2024-08    
CellCarta License                
Loss Contingencies [Line Items]                
Percentage of royalty payments on net revenue 0.675%              
Percentage of fee payments on net sales 1.00%              
Term of royalty payments from first commercial sale 15 years              
Year of ending royalty payments from first commercial sale 2034              
Royalty expense       100,000 100,000 $ 200,000 100,000  
AVEO Oncology                
Loss Contingencies [Line Items]                
Research and development       0 $ 0 0 $ 0  
Obligations related to agreement.       $ 0   $ 0    
AVEO Oncology | Ficlatuzumab                
Loss Contingencies [Line Items]                
Percentage of development and regulatory costs exercised using opt-out right     50.00%          
Percentage of royalty payments on net sales   10.00%            
Percentage of license income generated from licensing   25.00%            
AVEO Oncology | NSCLC POC Trial                
Loss Contingencies [Line Items]                
Responsible percentage of development and regulatory costs               50.00%